University of Oxford receives £7.8 million to fight pandemic threats
The Oxford Vaccine Group (OVG), which led the development of the Oxford vaccine for Covid-19, has been awarded a total of £7.8 ($9.8) million by UK Aid for research into the prevention of five diseases with epidemic or pandemic potential.
The awards will fund research into vaccines against Chikungunya and mayaro virus, Marburg virus, Plague (Yersinia pestis), Q Fever (Coxiella burneti) and Sudan Ebolavirus.
Professor Sir Andrew Pollard, Director of OVG and the Ashall Professor of Infection and Immunity at the Pandemic Sciences Institute, said: “The recent pandemic has highlighted the importance of making vaccines against potential threats to humanity. This critical work will help prevent future outbreaks in low- and middle-income countries and offer protection against future pandemics, as previously realised with the Oxford/AstraZeneca vaccine for Covid-19.”
The Department of Health and Social Care (DHSC), as part of UK Vaccine Network (UKVN), has made these financial awards to a UK Aid programme, to develop vaccines for diseases with epidemic potential in low and middle-income countries (LMICs).
Professor Teresa Lambe, Calleva Head of Vaccine Immunology at the Department of Paediatrics, and a Professor of Vaccinology and Immunology at OVG and the Pandemic Sciences Institute, said: “These awards are another important milestone in pandemic prevention. This funding will not only support our efforts to develop life-saving protection for people in low and middle-income countries, but will ensure the UK can respond quickly to potential future pandemic threats.”
